Invitrogen to buy BioReliance

Dec. 30, 2003 — Invitrogen Corp., a Carlsbad, Calif., provider of pharmaceutical and biotech research products and services, announced it has signed a definitive agreement to acquire BioReliance Corp., a contract test, development and manufacturing service provider for drugs and other products.

null

Invitrogen expects the deal, estimated at $500 million, will commence within 10 business days. Invitrogen expects to offer $48 per BioReliance share. Both companies’ boards of directors have approved the transaction, which is expected to close near the end of the first quarter.

null

BioReliance will retain its name and become part of Invitrogen’s bioproduction business segment.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.